Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Carcinoma, Non Small Cell Lung

In brief

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Key facts

Study ID

NCT01671332

Run by

University of Wisconsin, Madison

People needed

80

Starts

2012-06-01

Expected to finish

2016-06-16

Last updated by the study team

2020-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically proven diagnosis of non-small cell lung cancer
• Documented disease progression after first-line chemotherapy for non-small cell lung cancer
• Stable and treated CNS metastasis is allowed
• Radiation must be completed at least 2 weeks prior to starting protocol treatment
• Major surgery must be completed at least 4 weeks prior to starting protocol treatment
• ECOG performance status 0-2
• Sexually active patients must use adequate contraception
• Adequate bone marrow function
• Adequate renal function
• Adequate liver function

You may not qualify if…

• Severe hypersensitivity reaction to docetaxel
• Pre-existing grade 3 or 4 neuropathy
• Women who are pregnant or breastfeeding
• Uncontrolled intercurrent illness
• Receipt of 3 or more prior chemotherapy regimens

Where it is running

• University of Wisconsin Carbone Comprehensive Cancer Center — Madison, Wisconsin, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.